Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck.

GUIDELINE TITLE
Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck.

BIBLIOGRAPHIC SOURCE(S)
National Institute for Health and Clinical Excellence (NICE). Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck. London (UK): National Institute for Health and Clinical Excellence (NICE); 2009 Jun. 27 p. (Technology appraisal guidance; no. 172).

GUIDELINE STATUS
This is the current release of the guideline

MAJOR RECOMMENDATIONS
Cetuximab in combination with platinum-based chemotherapy is not recommended for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck.

People currently receiving cetuximab in combination with platinum-based chemotherapy for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck should have the option to continue treatment until they and their clinician consider it appropriate to stop.



open here to see the full-text:
Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck.